Opko Health (OPK) EBITDA (2010 - 2026)

Opko Health has reported EBITDA for 17 years, with the latest figure at -$51.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 24.05% year-over-year to -$51.0 million; the trailing twelve-month figure through Mar 2026 stood at -$34.5 million (up 87.09% YoY), and the FY2025 full-year result was -$50.7 million, up 66.66% from the prior year.
• EBITDA for Q1 2026 stood at -$51.0 million, down from $28.4 million in the prior quarter.
• The five-year high for EBITDA was $48.1 million in Q3 2025, with the low at -$87.8 million in Q3 2022.
• Historically, EBITDA has averaged -$42.8 million across 5 years, with a median of -$60.8 million in 2024.
• Annual changes were most pronounced in 2024 — EBITDA sank 977.86% — and 2025, when it soared 171.55%.
• Opko Health's EBITDA stood at -$55.3 million in 2022, then declined by 24.93% to -$69.0 million in 2023, then climbed by 2.72% to -$67.2 million in 2024, then soared by 142.28% to $28.4 million in 2025, then sank by 279.64% to -$51.0 million in 2026.
• The last three EBITDA figures came in at -$51.0 million (Q1 2026), $28.4 million (Q4 2025), and $48.1 million (Q3 2025), per Business Quant data.